FMP
Oramed Pharmaceuticals Inc.
ORMP
NASDAQ
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
2.27 USD
0.07 (3.08%)
About
ceo
Mr. Nadav Kidron Esq.
sector
Healthcare
industry
Biotechnology
website
https://www.oramed.com
exchange
NASDAQ
Description
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its n...
CIK
0001176309
ISIN
US68403P2039
CUSIP
68403P203
Address
1185 Avenue of the Americas
Phone
844 967 2633
Country
US
Employee
13
IPO Date
May 1, 2007
Summary
CIK
0001176309
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
68403P203
ISIN
US68403P2039
Country
US
Price
2.27
Beta
1.82
Volume Avg.
173.44k
Market Cap
91.98M
Shares
-
52-Week
1.67-5.25
DCF
0.32
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
16.21
P/B
-
Website
https://www.oramed.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ORMP News
It looks like there's no news available.
